🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06569953
Recruiting Phase 4

Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial

NCT06569953 · tracked via the Priya Life Science China tracker
Sponsor
The Second Affiliated Hospital of Chongqing Medical University
Phase
Phase 4
Started
2024-08-26
Last updated
2025-06-27

Condition(s) studied

Acute PainChronic PainPostoperative Pain

Investigational drug(s) / intervention(s)

Liposomal bupivacaineBupivacaine Hydrochloride

Liposomal bupivacaine: Participants randomized to the intervention arm received 266 mg of liposomal bupivacaine for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline).

Bupivacaine Hydrochloride: Participants randomized to the intervention arm received 0.5% 100 mg of bupivacaine hydrochloride for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline)

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of liposomal Bupivacaine administered by paravertebral block for the treatment of acute and chronic pain after video-assisted thoracoscopic lobectomy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Participants who scheduled for elective video-assisted thoracoscopic lobectomy under general anesthesia. * Participants were 18 years or older. * 18 kg/m2≤BMI≤30 kg/m2 * Participants with American Society of Anesthesiology (ASA) physical status I-III. * Understand the significance, possible benefits, potential risks of the trial in detail.Understand the procedures and methods of this study.Willing to complete the trial in strict compliance with the clinical trial protocol.Sign the informed consent form voluntarily. Exclusion Criteria: * with severe cardiovascular and cerebrovascular diseases such as myocardial infarction,unstable angina pectoris,severe cardiac rhythm disorders (second- and third-degree heart block,etc.), New York Heart Association (NYHA) functional class III/IV,Ischemic stroke. * with psychiatric disorders (such as schizophrenia,depression,etc.) and cognitive impairment. * with sensory disorders such as hyperalgesia. * with other bodily pain. * allergy to amide-type local anesthetics or any of the trial drugs * taking drugs that affect liver metabolism,corticosteroids,benzodiazepines,non-steroidal anti-inflammatory drugs(NSAIDs),opioid agonist-antagonist,central-alpha 2-agonists,anticonvulsants,antidepressants within 72h. * with a history of alcohol or opioid abuse. * who were pregnant or lactating. * who were currently included in another clinical study within 3 months.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Second Affiliated Hospital of Chongqing Medical University Chongqing Chongqing Municipality Recruiting

More The Second Affiliated Hospital of Chongqing Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06569953 on ClinicalTrials.gov ↗ ← All trials in China